Daxor Corporation
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Michael Richard Feldschuh
- Full Time Employees
- 37
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Address
- 109 Meco Lane Oak Ridge TN United States of America 37830
- IPO Date
- Jul 25, 1983
- CIK
- 0000027367
- Website
- daxor.com
- Similar Companies
- Business
- Daxor Corporation specializes in developing, manufacturing, and marketing proprietary blood volume measurement technology for healthcare applications. Its core products include the FDA-cleared BVA-100 Blood Volume Analyzer system and associated single-use Volumex diagnostic kits, which provide direct, quantitative measurements of total blood volume, red blood cell volume, and plasma volume using a micro-dose I-131 albumin tracer. These products are primarily used in hospital intensive care units, emergency departments, cardiology, and nephrology to optimize fluid management in patients with conditions such as heart failure, sepsis, and critical care needs. In addition to the BVA system, Daxor offers the Glofil diagnostic, a glomerular filtration rate (GFR) measurement drug, expanding its product portfolio to better serve overlapping hospital customer bases focused on blood volume and kidney function diagnostics. Recent major developments include the company's acquisition of exclusive worldwide manufacturing rights and intellectual property for Volumex and Megatope diagnostics from Iso-Tex Diagnostics, along with the addition of the Glofil diagnostic product. These acquisitions, announced in 2024, are designed to bring manufacturing in-house at Daxor’s Oak Ridge, Tennessee facility, improve margins, increase revenue streams, and add a significant cross-sell product offering. In 2025, Daxor achieved FDA clearance for a next-generation rapid, lightweight Blood Volume Analysis system and expanded its market penetration with new contract signings and facility adoptions across multiple U.S. healthcare systems. The company experienced a 73% revenue increase for the first half of 2025 compared to the prior year, driven by sales of single-use diagnostic kits and military contracts. The firm also reported expansion into new hospital networks, including a significant lease agreement covering 24 affiliated hospitals in several U.S. states. Founded over 50 years ago and headquartered in Oak Ridge, Tennessee, Daxor operates globally but is primarily focused on the U.S. healthcare market. It targets hospitals, healthcare systems, and clinical departments requiring precise fluid management solutions. The company emphasizes clinical validation of its technology, which supports improved patient outcomes and cost-effective care pathways. Daxor’s leadership includes President and CEO Michael Feldschuh, who actively engages with institutional investors and promotes the company's mission to advance healthcare through precise blood volume measurement technology. Daxor’s business segments span diagnostic technology manufacturing, direct sales, and clinical support services centered around its blood volume analysis platform and related products. This combination of technological innovation, strategic acquisitions, regulatory clearances, and expanding clinical adoption positions Daxor Corporation as a leader in blood volume measurement diagnostics within the biotechnology and healthcare industry sectors. The company is focused on continuing its commercial rollout and research and development efforts to improve and extend its product offerings across critical care and cardiovascular markets.
Daxor Corporation Receives U.S. Patent for Breakthrough Remote Blood Volume Monitor
Daxor Leverages MedAxiom CV Transforum Spring'26 to Accelerate Commercial Adoption of Blood Volume Analysis
Daxor Expands Customer Footprint with New BVA Program at High-Volume Ohio Cardiology Center
Daxor's Blood Volume Analysis Metric Validated as Uniquely Accurate Versus Capillary Leak Indexes in New Clinical Data Presented at SCCM 2026
Daxor Corporation to Showcase Next-Generation Portable Blood Volume Analyzer at ACC.26; Highlighting Clinical Outcomes and Reduced Readmissions
Daxor Corporation (DXR) Presents at IAccess Alpha Virtual Best Ideas Spring Investment Conference 2026 Prepared Remarks Transcript
Daxor to Debut New Rapid, Portable Blood Volume Analyzer at SCCM 2026 Critical Care Congress
Daxor Corporation to Participate in the iAccess Virtual Alpha Best Ideas Spring Investment Conference 2026
Daxor Corporation Reports 2025 Fiscal Year Results: Operating Revenue Up 45%, Net Asset Value Rises to $9.07 Per Share
Daxor (NASDAQ:DXR) vs. Addus HomeCare (NASDAQ:ADUS) Financial Survey
Daxor Scales Outpatient Presence; Launches BVA Diagnostic Program in Tennessee
RadNet (NASDAQ:RDNT) & Daxor (NASDAQ:DXR) Head to Head Analysis
Daxor Corporation Announces Transition To Securities Exchange Act of 1934 Reporting Company, Reaffirming Focus on Core Blood Volume Analysis and Diagnostic Business
Contrasting Daxor (NASDAQ:DXR) and Quest Diagnostics (NYSE:DGX)
Daxor Corporation Announces $9 Million Registered Direct Offering
Quest Diagnostics (NYSE:DGX) & Daxor (NASDAQ:DXR) Head-To-Head Review
Analyzing Daxor (NASDAQ:DXR) and Elanco Animal Health (NYSE:ELAN)
Daxor (NASDAQ:DXR) Trading Down 1.4% – Here’s Why
Daxor Fuels Growth with Three New Facility Adoptions and Deployment of Next-Generation BVA Analyzer
Daxor CEO Michael Feldschuh to Engage Investors at Exclusive Maxim Growth Summit